{"denoms":[{"counts":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"63"},{"groupId":"BG002","value":"123"},{"groupId":"BG003","value":"196"}],"units":"Participants"}],"groups":[{"description":"IMRT for seven weeks, 5 fractions/week. Durvalumab 1500 mg IV starts two weeks prior to RT and continues every 4 weeks for a total of seven cycles in the absence of disease progression or unacceptable toxicity.","id":"BG000","title":"(Lead-in) RT + Durvalumab"},{"description":"IMRT for seven weeks, 5 fractions/week. Cetuximab 400 mg/m\\^2 IV starts one week prior to RT, then 250 mg/m\\^2 weekly for seven additional cycles in the absence of disease progression or unacceptable toxicity.","id":"BG001","title":"RT + Cetuximab"},{"description":"IMRT for seven weeks, 5 fractions/week. Durvalumab 1500 mg IV starts two weeks prior to RT and continues every 4 weeks for a total of seven cycles in the absence of disease progression or unacceptable toxicity.","id":"BG002","title":"RT + Durvalumab"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"4"}]}],"title":"≤ 49 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"19"}]}],"title":"50 - 59 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"35"},{"groupId":"BG003","value":"61"}]}],"title":"60 - 69 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"60"},{"groupId":"BG003","value":"88"}]}],"title":"70 - 79 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"16"},{"groupId":"BG003","value":"24"}]}],"title":"≥ 80 years"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"21"},{"groupId":"BG003","value":"31"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"54"},{"groupId":"BG002","value":"102"},{"groupId":"BG003","value":"165"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"14"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"56"},{"groupId":"BG002","value":"117"},{"groupId":"BG003","value":"173"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"9"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"2"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"3"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"17"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"50"},{"groupId":"BG002","value":"105"},{"groupId":"BG003","value":"165"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"7"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"48"},{"groupId":"BG003","value":"80"}],"title":"0"},{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"60"},{"groupId":"BG003","value":"93"}],"title":"1"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"15"},{"groupId":"BG003","value":"23"}],"title":"2"}]}],"description":"0 - Asymptomatic; 1 - Symptomatic but completely ambulatory; 2 - Symptomatic, \\<50% in bed during the day; 3 - Symptomatic, \\>50% in bed, but not bedbound; 4 - Bedbound; 5 - Death","paramType":"COUNT_OF_PARTICIPANTS","title":"Zubrod performance status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"43"},{"groupId":"BG003","value":"71"}],"title":"0 (no comorbidities)"},{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"80"},{"groupId":"BG003","value":"125"}],"title":"≥ 1"}]}],"description":"An assessment tool used to predict the mortality for a patient who may have a range of concurrent conditions (comorbidities). The score ranges from 0 (no comorbidities) to 35 (highest possible comorbidity load / highest risk of death). For this study, the CCI was modified to exclude the cancer questions: \"Has the patient had cancer (other than basal cell skin cancer)?\" and \"Has the patient had a metastatic solid tumor?\".","paramType":"COUNT_OF_PARTICIPANTS","title":"Modified Charlson Comorbidity Index (CCI)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"55"},{"groupId":"BG003","value":"88"}],"title":"Oropharynx, p16-positive"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"6"}],"title":"Unknown, p16-positive"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"15"},{"groupId":"BG003","value":"20"}],"title":"Oropharynx, p16-negative"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"}],"title":"Unknown, p16-negative"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"10"}],"title":"Oral cavity"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"13"},{"groupId":"BG003","value":"21"}],"title":"Hypopharynx"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"30"},{"groupId":"BG003","value":"50"}],"title":"Larynx"}]}],"description":"The biomarker p16 is used as a surrogate marker for human papillomavirus (HPV) infections and is a known prognostic factor in some head and neck cancers.","paramType":"COUNT_OF_PARTICIPANTS","title":"Primary tumor site and p16 status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"7"}],"title":"T0"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"21"}],"title":"T1"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"38"},{"groupId":"BG003","value":"56"}],"title":"T2"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"42"},{"groupId":"BG003","value":"65"}],"title":"T3"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"15"},{"groupId":"BG003","value":"28"}],"title":"T4"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"17"}],"title":"T4a"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"2"}],"title":"T4b"}]}],"description":"Tumor stage per the American Joint Committee on Cancer (AJCC) refers to the size and/or extent of the main tumor. The higher the number after the T, the larger the tumor or the more it has grown into nearby tissues. T's may be further divided to provide more detail, such as T3a and T3b. Lead-in component used 7th edition of AJCC; phase II component used 8th edition.","paramType":"COUNT_OF_PARTICIPANTS","title":"T stage, clinical (AJCC 8)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"17"},{"groupId":"BG003","value":"31"}],"title":"N0"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"36"},{"groupId":"BG003","value":"66"}],"title":"N1"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"21"},{"groupId":"BG003","value":"29"}],"title":"N2"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"2"}],"title":"N2a"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"21"},{"groupId":"BG003","value":"28"}],"title":"N2b"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"17"},{"groupId":"BG003","value":"30"}],"title":"N2c"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"4"}],"title":"N3"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"2"}],"title":"N3a"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"4"}],"title":"N3b"}]}],"description":"Regional lymph nodes staging per American Joint Committee on Cancer (AJCC) 7th ed. refers to the number and/or extent of spread of lymph nodes that contain cancer. The higher the number after the N, the greater the involvement of regional lymph nodes. Lead-in component used 7th edition of AJCC; phase II component used 8th edition.","paramType":"COUNT_OF_PARTICIPANTS","title":"N stage, clinical (AJCC 8)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"35"},{"groupId":"BG003","value":"60"}],"title":"≤ 10 pack-years"},{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"42"},{"groupId":"BG002","value":"88"},{"groupId":"BG003","value":"136"}],"title":"> 10 pack-years"}]}],"description":"A way to measure the amount a person has smoked over a long period of time. It is calculated by multiplying the number of packs of cigarettes smoked per day by the number of years the person has smoked.","paramType":"COUNT_OF_PARTICIPANTS","title":"Smoking history: pack-years","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"52"},{"groupId":"BG002","value":"104"},{"groupId":"BG003","value":"162"}],"title":"Absolute or relative contraindication to cisplatin"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"17"}],"title":"Age ≥ 70 with moderate to severe comorbidity or vulnerability to cisplatin"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"17"}],"title":"Age < 70 with severe comorbidity or vulnerability to cisplatin"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Comorbidity group","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"}],"title":"1"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"9"}],"title":"2"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"20"}],"title":"3"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"23"},{"groupId":"BG003","value":"37"}],"title":"4"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"31"},{"groupId":"BG003","value":"50"}],"title":"5"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"53"},{"groupId":"BG003","value":"79"}],"title":"≥ 6"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Number of comorbidity conditions","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"comment":"The lead-in component was not randomized and therefore participants were not stratified.","groupId":"BG000","value":"NA"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"20"},{"comment":"Total not calculated because data are not available (NA) in one or more arms.","groupId":"BG003","value":"NA"}],"title":"Zubrod 0 and modified CCI 0"},{"measurements":[{"comment":"The lead-in component was not randomized and therefore participants were not stratified.","groupId":"BG000","value":"NA"},{"groupId":"BG001","value":"50"},{"groupId":"BG002","value":"103"},{"comment":"Total not calculated because data are not available (NA) in one or more arms.","groupId":"BG003","value":"NA"}],"title":"Zubrod 1-2 and/or modified CCI > 0"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Stratification factor: Zubrod and modified CCI","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"comment":"The lead-in component was not randomized and therefore participants were not stratified.","groupId":"BG000","value":"NA"},{"groupId":"BG001","value":"30"},{"groupId":"BG002","value":"58"},{"comment":"Total not calculated because data are not available (NA) in one or more arms.","groupId":"BG003","value":"NA"}],"title":"p16-positive oropharynx or unknown primary"},{"measurements":[{"comment":"The lead-in component was not randomized and therefore participants were not stratified.","groupId":"BG000","value":"NA"},{"groupId":"BG001","value":"33"},{"groupId":"BG002","value":"65"},{"comment":"Total not calculated because data are not available (NA) in one or more arms.","groupId":"BG003","value":"NA"}],"title":"p16-negative oropharynx or unknown primary, larynx, hypopharynx or oral cavity"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Stratification factor: primary site and p16 status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"comment":"The lead-in component was not randomized and therefore participants were not stratified.","groupId":"BG000","value":"NA"},{"groupId":"BG001","value":"45"},{"groupId":"BG002","value":"88"},{"comment":"Total not calculated because data are not available (NA) in one or more arms.","groupId":"BG003","value":"NA"}],"title":"T0-3 and N0-2"},{"measurements":[{"comment":"The lead-in component was not randomized and therefore participants were not stratified.","groupId":"BG000","value":"NA"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"35"},{"comment":"Total not calculated because data are not available (NA) in one or more arms.","groupId":"BG003","value":"NA"}],"title":"T4 and/or N3"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Stratification factor: T and N stage","unitOfMeasure":"Participants"}],"populationDescription":"Enrolled participants (i.e. for phase II, randomized)"}